Inhibition of Aldose Reductase Activates Hepatic Peroxisome Proliferator-Activated Receptor-<i>α</i> and Ameliorates Hepatosteatosis in Diabetic db/db Mice

<table>Effects of AR on PPAR<i>α</i> and ERK1/2 phosphorylation in db/db mice. (a) Representative Western blot for four independent experiments. Liver tissues were dissected and analyzed 28 days after zopol treatment. (b) Representative Western blot for four independent experiments. Liver tissues were dissected and analyzed 28 days after transduction with lentiviruses containing pLV-shAR or pLV-shNC. pERK1/2, phospho-ERK1/2; pPPAR<i>α</i> (S12), phosphoserine-12 PPAR<i>α</i>; pPPAR<i>α</i> (S21), phosphoserine-21 PPAR<i>α</i>.</table>

Journal of Diabetes Research

fig3

Figure 3

Figure 3: Inhibition of Aldose Reductase Activates Hepatic Peroxisome Proliferator-Activated Receptor-<i>α</i> and Ameliorates Hepatosteatosis in Diabetic db/db Mice 

Figure 3 | Inhibition of Aldose Reductase Activates Hepatic Peroxisome Proliferator-Activated Receptor-α and Ameliorates Hepatosteatosis in Diabetic db/db Mice 